MCM
CYTK icon

MV Capital Management’s Cytokinetics CYTK Stock Holding History

MV Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.61K Buy
70
+1
+1% +$64 ﹤0.01% 638
2025
Q4 		$4.38K Hold
69
– – ﹤0.01% 623
2025
Q3 		$3.79K Buy
69
+1
+1% +$41 ﹤0.01% 634
2025
Q2 		$2.25K Buy
68
+61
+871% +$2.12K ﹤0.01% 695
2025
Q1 		$282 Sell
7
-6
-46% -$276 ﹤0.01% 885
2024
Q4 		$612 Buy
+13
New +$675 ﹤0.01% 791

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MV Capital Management's CYTK Position: Q1 2026 in Review

MV Capital Management increased its Cytokinetics (CYTK) stake by 1.4% in Q1 2026, buying an estimated $64 and bringing the position to 70 shares worth $4.61K. The position accounts for ﹤0.01% of the portfolio, ranked #638.

MV Capital Management first reported a position in CYTK in Q4 2024 and has held it in 6 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • MV Capital Management held 70 shares of Cytokinetics worth $4.61K as of Q1 2026.
  • MV Capital Management bought 1 Cytokinetics share in Q1 2026, an estimated $64.
  • Cytokinetics made up ﹤0.01% of MV Capital Management's portfolio in Q1 2026, its #638 holding.
  • MV Capital Management first reported a position in Cytokinetics in Q4 2024 and has held it in 6 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on MV Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.